Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoantigen mRNA Vaccine + Sintilimab in Advanced Solid Tumors
NCT05949775Phase 1Not yet recruiting
- Sponsor
- Stemirna Therapeutics
- Start
- Jul 2023
- Primary completion
- Dec 2025
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of SW-H-201 in Advanced Malignant Solid Neoplasm (AMSN), sponsored by Stemirna Therapeutics. Primary endpoint: Progression-Free Survival at 24 months. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
SW-H-201
03
Conditions
Advanced Malignant Solid Neoplasm (AMSN)
Beyond the preview
Go deeper on NCT05949775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05949775.